The operating activities of the Merck Group are organized into four divisions. The Merck Serono division develops, manufactures and markets prescription drugs to treat neurodegenerative diseases, cancer, infertility, cardiovascular diseases and selected metabolic disorders. More than 60% of Merck Serono’s sales are generated with biologics, making the division one of Europe’s leading suppliers of biopharmaceuticals. In the third quarter of 2013, Merck Serono accounted for around 56% of Group sales. The Consumer Health division manufactures and markets over-the-counter pharmaceuticals that primarily address health themes such as mobility, women’s and [...]

[...] year. In a first step, the allocation of expenses for Group functions of Merck KGaA to the operating divisions was modified in fiscal 2012. In a further step, the corresponding disclosures for the consolidated subsidiaries were adjusted in fiscal 2013. Consequently, expenses for Group functions are no longer allocated to the operating divisions, but rather disclosed fully in the column “Corporate and Other” in the Segment Reporting. In order to ensure comparability, the previous year’s Segment Reporting figures have been adjusted in accordance with the allocation rules for 2013. The notes to the consolidated financial statements of the Merck Group for 2012, [...]

[...] of 2013, the strong euro led to significant negative exchange rate effects that burdened all four divisions. Above all, the exchange rate developments of the Japanese yen, U.S. dollar as well as Latin American currencies were responsible for this. Acquisitions increased sales by 0.2%. Overall, Group sales totaled € 2,659 million (Q3 2012: € 2,722 million). Three of the four divisions achieved sound organic sales growth in the third quarter of 2013 with the greatest absolute contributions coming from Merck Serono, which accounts for the majority of Group sales and reported organic growth of 5.2%, as well as Merck Millipore with organic sales growth of 5.9%. The [...]

Corporate and Other comprises Group administration expenses for Group functions that cannot be directly allocated to the divisions. This includes Group functions such as Finance, Procurement, Legal, Communications, and Human Resources. Corporate costs also include expenses for central, non-allocated IT functions, also related to the expansion and harmonization of IT systems within the Merck Group. As a result, Corporate and Other has no sales to report. Gains or losses on currency hedging are also reported in Corporate and Other. XLS Corporate and Other | Key figures € million Q3 – 2013 Q3 – 2012 Change Jan.–Sept. 2013 Jan.–Sept. 2012 Change Total [...]

[...] is expecting the following business performance for the full year 2013: XLS Guidance for FY 2013 Merck divisions Sales EBITDA pre one-time items € million Merck Serono Moderate organic growth ~ 1,900 – 2,000 Consumer Health Moderate organic growth ~ 73 – 77 Performance Materials ~ Stable ~ 750 – 770 Merck Millipore Moderate organic growth ~ 620 – 640 Corporate and Other ~ –210 Merck Group € billion Sales ~ 10.7 – 10.9 EBITDA pre one-time items ~ 3.2 – 3.25 EPS pre one-time items ~ € 8.50 – 9.00 FX assumptions for FY 2013: 1 € = 1.33 US$ 1 € = 1.23 CHF 1 € = 130 JPY